Search

Displaying results 3481 - 3490 of 10000 in total
  1. Drug

    Midomafetamine

    go.drugbank.com/drugs/DB01454
    IllicitInvestigational

    An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. … It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems.

  2. Drug

    Pegamotecan

    go.drugbank.com/drugs/DB12842
    Investigational

    Pegamotecan has been used in trials studying the treatment of Cancer of Stomach, Sarcoma, Soft Tissue, and Gastroesophageal Cancer.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Deoxyspergualin

    go.drugbank.com/drugs/DB12991
    Investigational

    Deoxyspergualin has been used in trials studying the treatment of Lupus Nephritis, Chronic Rejection, and Diabetes Mellitus, Type 1.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Amitraz

    go.drugbank.com/drugs/DB11373
    ExperimentalVet approved

    It was generated in 1969 by the Boots Co. in England. Amitraz presents insect repellent effects and hence, it can be used as an insecticide and pesticide. … Amitraz presents a lower effect in mammals and thus, it is widely used in the treatment of mite- or tick-infestation of dogs.

    Categories: Compounds used in a research, industrial, or household settingSynonyms: N,N'-(methyliminodimethylidyne)bis-2,4-xylidine
  5. Drug

    Pheniprazine

    go.drugbank.com/drugs/DB09250
    ApprovedWithdrawn

    Pheniprazine is an irreversible and nonselective monoamine oxidase inhibitor (MAOI) of the hydrazine chemical class that was used as an antidepressant in the 1960s. … In addition, it was used for the treatment of other conditions, such as angina pectoris and schizophrenia.

  6. Drug

    Albinterferon Alfa-2B

    go.drugbank.com/drugs/DB05396
    Investigational

    In response to an FDA ruling, Novartis and Human Genome Sciences announced on October 5, 2010 that they ceased development of the drug. … The drug was under investigation as an alternative to pegylated IFN-α-2a for the treatment of hepatitis C.

  7. Drug

    Pancuronium

    go.drugbank.com/drugs/DB01337
    Approved

    As a neuromuscular blocking agent it is more potent than curare but has less effect on the circulatory system and on histamine release.

  8. Drug

    Rindopepimut

    go.drugbank.com/drugs/DB05374
    Investigational

    Rindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases. … The US FDA granted it Breakthrough Therapy Designation for glioblastoma in Feb 2015.

  9. Drug

    DP-VPA

    go.drugbank.com/drugs/DB05821
    Investigational

    DP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure

  10. Drug

    Idarucizumab

    go.drugbank.com/drugs/DB09264
    Approved

    Idarucizumab is a humanized monoclonal antibody fragment (Fab) derived from an immunoglobulin G1 isotype molecule that binds to and inactivates the oral anticoagulant dabigatran, thereby reversing its … Approved under the tradename Praxbind (FDA), idarucizumab is indicated for the emergency treatment of dabigatran-associated bleeding in life-threatening or surgically induced situations.